Halozyme Therapeutics/ US40637H1095 /
2024-07-26 9:59:55 PM | Chg. +0.28 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
56.23USD | +0.49% | 24,769 Turnover: 1.39 mill. |
-Bid Size: - | -Ask Size: - | 57.09 | 55.63 |
GlobeNewswire
05-06
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conferenc...
GlobeNewswire
2023-11-06
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develo...
GlobeNewswire
2022-02-22
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
GlobeNewswire
2021-09-02
Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Off...
GlobeNewswire
2021-06-30
TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Progra...
GlobeNewswire
2021-05-26
Novome Biotechnologies Appoints Dr. David N. Cook and Zachary Hornby to its Board of Directors
GlobeNewswire
2021-05-12
Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer
GlobeNewswire
2020-09-22
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
GlobeNewswire
2019-07-02
Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors
GlobeNewswire
2019-06-11
Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors
GlobeNewswire
2019-02-28
FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
GlobeNewswire
2019-02-15
Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Car...
GlobeNewswire
2019-02-04
argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology
GlobeNewswire
2018-12-27
Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor ...
GlobeNewswire
2018-12-11
Biopharmaceutical Drug Delivery Device Technology - Global Markets to 2023: Trends & Developments